Gina Duggar, NP
Nurse Practitioner · Carrollton, GANPI 1639174600
Payments from drug & device makers
Across 169 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Seagen Inc.$786
- Astellas Pharma US Inc$273
- Lilly USA, LLC$165
- Novartis$157
- Eisai Inc.$156
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,24872%
- Education$1,24828%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 42 | $1,015 |
| Seagen Inc. | 25 | $786 |
| Astellas Pharma US Inc | 5 | $273 |
| Lilly USA, LLC | 5 | $165 |
| Novartis | 7 | $157 |
| Eisai Inc. | 8 | $156 |
| Johnson & Johnson | 4 | $153 |
| Incyte Corporation | 3 | $140 |
| Bayer | 6 | $137 |
| Merck | 5 | $131 |
| Daiichi Sankyo Inc. | 5 | $122 |
| Geron Corporation | 4 | $100 |
| Amgen | 2 | $97 |
| Genentech USA, Inc. | 3 | $88 |
| E.r. Squibb & Sons, L.L.C. | 4 | $86 |
| AbbVie | 3 | $82 |
| Jazz Pharmaceuticals Inc. | 2 | $80 |
| Sobi, Inc | 3 | $67 |
| AstraZeneca(2 entities) | 3 | $64 |
| Karyopharm Therapeutics Inc. | 3 | $61 |
| Bristol Myers Squibb | 3 | $53 |
| Exelixis Inc. | 2 | $46 |
| Puma Biotechnology, Inc. | 2 | $44 |
| Gilead | 2 | $43 |
| Caris MPI, Inc. | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Array Biopharma Inc | 3 | $29 |
| Deciphera Pharmaceuticals Inc. | 1 | $25 |
| Beigene USA, Inc. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Sanofi | 1 | $21 |
| GSK | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $14 |
How this compares
$4,496 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 21 | $314 |
| Anastrozole | 23 | $244 |
| Ondansetron Hcl | 22 | $163 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Carrollton
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.